doctor prescribed semaglutide metairie new orleans Orleans Primary Care 🌸 MARCH INTO WELLNESS 🌸,

Eli Lilly submitted the orforglipron NDA to the FDA in Q1 2026 following ATTAIN Phase 3 trial data showing 14.7% body weight reduction at 45mg positioning the worlds first oral small molecule GLP-1 receptor agonist for obesity for anticipated FDA approval in late 2026 or 2027

At 10 years, the survival probability was 96.9% for GLP-1RA use and 76.4% for insulin/metformin use

Impact of protein on PCOS PCOS is a common disorder of the endocrine system that usually occurs in women of reproductive age and is often associated with obesity, insulin resistance, and hormonal imbalances

7), which remained significant after controlling for diabetes